GLP-1 analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
== Indications/Symptoms == Typical symptoms after being bitten by a black mamba include the rapid onset of dizziness, drowsiness and coughing and having difficulties breathing. Other likely symptoms include convulsions, neuromuscular symptoms, shock, loss of consciousness, hypotension, ataxia, excessive salivation, limb paralysis, nausea and vomiting, fever, and severe abdominal pain. Permanent limb paralysis is very likely if the bite remains untreated. In the most severe case, if untreated, the bite of the black mamba can lead to death by suffocation, resulting from the paralysis of respiratory muscles. All these symptoms are due to a combination of all the toxic peptides the crude venom of the black mamba contains. The symptoms are related to calciseptine because it also works as a smooth muscle relaxant, thus explaining the early onset of having difficulties breathing, limb paralysis and even death by suffocation. Calciseptine is known to have a hypotensive effect. It cannot clearly be established which peptide is most responsible for which symptom, since combinations of different toxins can have various effects.
=== Sequencing insulin === Neuberger moved to the National Institute for Medical Research in London, but Sanger stayed in Cambridge and in 1943 joined the group of Charles Chibnall, a protein chemist who had recently taken up the chair in the Department of Biochemistry. Chibnall had already done some work on the amino acid composition of bovine insulin and suggested that Sanger look at the amino groups in the protein. Insulin could be purchased from the pharmacy chain Boots and was one of the very few proteins that were available in a pure form. Up to this time Sanger had been funding himself. In Chibnall's group he was initially supported by the Medical Research Council and then from 1944 until 1951 by a Beit Memorial Fellowship for Medical Research. Sanger's first triumph was to determine the complete amino acid sequence of the two polypeptide chains of bovine insulin, A and B, in 1952 and 1951, respectively. Prior to this it was widely assumed that proteins were somewhat amorphous. In determining these sequences, Sanger proved that proteins have a defined chemical composition. To get to this point, Sanger refined a partition chromatography method first developed by Richard Laurence Millington Synge and Archer John Porter Martin to determine the composition of amino acids in wool. Sanger used a chemical reagent 1-fluoro-2,4-dinitrobenzene (now, also known as Sanger's reagent, fluorodinitrobenzene, FDNB or DNFB), sourced from poisonous gas research by Bernard Charles Saunders at the Chemistry Department at Cambridge University.
=== Novel mAb development technology === Several monoclonal antibody technologies were developed in the period from the 1970s to the late 2010s, such as phage display, single B cell culture, single cell amplification from various B cell populations and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the more recent technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is their applicability to multiple animals, such as rabbit, llama, chicken and other common experimental animals in the laboratory.
Sources: en.wikipedia.org
== Target == Do6a primarily targets Pickpocket/Balboa (Ppk/Bba or Ppk1/Ppk26) ion channels that are evenly distributed on the dendrites of class IV dendritic arborizing (cIV da) neurons in the peripheral nervous system of fruit fly larvae. cIV da neurons are responsible specifically for nociception from mechanical stimuli and heat, unlike cI, cII cIII that respond to other sensory input, like proprioception or gentle touch. These neurons have highly complex dendritic trees and blocking their synaptic output significantly reduces behavioral nociceptive responses (e.g. rolling) in larvae. Do6a appears to target exclusively insect nociceptors, likely due to the parasitic reproduction cycle of the species requiring good protection against other insects. Other peptides in the venom (e.g. Do10a and Do13a) affect pain receptors in mammals. Expression of both Ppk and Bba forming a heteromeric channel complex in cIV da neurons are necessary for nociception from Do6a. Ppk/Bba belong to Degenerin/Epithelial (DEG/ENaC) protein family and respond specifically to mechanical nociception and not noxious heat. Gating of these channels is still not entirely understood. While their activation upon harsh mechanical pressure may suggest a mechanosensitive nature of these channels, peptides like Do6a and Vulnusin have been shown to activate Ppk1/Ppk26 without a presence of a mechanical stimulus, pointing towards ligand-gating instead.
== Future directions == Future research on PMPs aims to refine their design, enhance biocompatibility, and expand their therapeutic applications. Efforts are focused on improving hemostatic performance by integrating biomimetic molecular, structural, and biophysical features, such as targeted peptide modifications, procoagulant components, and optimized particle geometry. Additionally, researchers are exploring the combination of synthetic platelet systems with other blood components to develop biosynthetic whole blood substitutes. Key challenges include ensuring scalability, assessing long-term safety, and evaluating immunogenic risks, particularly for repeated dosing. Ongoing research is focused on optimizing these factors through interdisciplinary collaboration to facilitate clinical translation.
=== Plant breeding === Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop. Some growers in the US succeeded in lowering the proportion of CBD-to-THC to accommodate customers who preferred varietals that were more mind-altering due to the higher THC and lower CBD content. In the US, hemp is classified by the federal government as cannabis containing no more than 0.3% THC by dry weight. This classification was established in the 2018 Farm Bill and was refined to include hemp-sourced extracts, cannabinoids, and derivatives in the definition of hemp.
In humans (and rodents), there are 3 major paired salivary glands and ~600-1000 smaller minor salivary glands. Serous acinar cells are primarily found in the parotid gland and the submandibular gland, while they are almost completely absent in the sublingual gland and most of the minor glands. The parotid gland is the largest of the salivary glands, and possesses acinar cells that are almost exclusively of the serous type. It produces around 50% of human saliva to help with digestion when stimulated, but only about 20% of saliva when resting. Consequently, the saliva it produces is watery and full of the enzyme α-Amylase, which helps break down carbohydrates. The submandibular gland produces the majority (~65%) of saliva in the resting state. It has a mix of serous and mucous acinar cells, and so the saliva it produces is thicker and full of mucus. In the submandibular gland, some acini are predominantly serous acinar cells (serous glands) or predominantly mucous acinar cells (mucous glands), while others are a mix (seromucous glands). The other salivary glands produce the last ~10% of saliva, and mainly possess mucous acinar cells. An exception is the set of Von Ebner glands, minor salivary glands located in the tongue that are primarily serous glands.
Sources: en.wikipedia.org
=== Awards === The Orange Box won a number of awards for its overall high standard and use of technology. The compilation won "Computer Game of the Year" at the Academy of Interactive Arts & Sciences' 11th Annual Interactive Achievement Awards; it also received nominations in the "Overall Game of the Year", "Action Game of the Year", and "Outstanding Innovation in Gaming" categories. The Orange Box won the "Breakthrough Technology Award" and the "Best PC Game Award" at the 2007 Spike Video Game Awards, and was additionally nominated in the "Game of the Year", "Best Shooter", "Best Xbox 360 Game", and "Best Multiplayer Game" categories. It was also named the second-best video game of 2007 by Time Magazine, while the PlayStation 3 version was nominated in the category of Action and Adventure at the BAFTA Video Games Awards. Valve also received developer awards for their work on The Orange Box. The Orange Box received 17 Game of the Year awards and over 100 awards in total. The Orange Box was placed as the 22nd most influential video game in history by the Guinness World Records Gamer's Edition, 2009. Portal won "Outstanding Achievement in Game Design", "Outstanding Achievement in Gameplay Engineering", and "Outstanding Character Performance" for Ellen McLain's vocal portrayal of GLaDOS at the 11th Annual Interactive Achievement Awards. The game won 76 awards, including 37 Game of the Year awards, and was recognized for innovative design and game mechanics. The dark humor of Portal and the ending music track "Still Alive" were also singled out for awards.
== Biochemical profile-based microbial identification systems == Phenotypic tests are used to identify microbes based on metabolic and biochemical pathways present in those microbes. There are many automated and semi-automated commercial systems available. These methods can be very informative but are not as accurate as MALDI-TOF or genotypic methods.
In April 2012, the government announced additional spending cuts in education and healthcare of 10 billion euros, which raised protests from the affected sectors. On May 22, 2012, the first general education strike in the history of Spain took place. Only three days later, on May 25, it was known that Bankia, nationalized two weeks earlier, would need an injection of 19 billion euros of public money to be cleaned up, highlighting the fragility of the Spanish banking system. On June 9, Finance Minister Luis de Guindos announced that Spain was going to ask for a financial rescue from the European Union for a maximum value of 100 billion euros to clean up the savings banks with problems, although he refused to use the term "rescue" and preferred the term "credit on very favorable terms". The same was done by President Mariano Rajoy in his speech the following day who used the term "credit line". However, the harsh policies of adjustment and "structural reforms" implemented by the government did not manage to stop the escalation of the risk premium which in July 2012 exceeded 600 basis points with respect to the German bond, a level that made it practically impossible to finance Spanish debt in the markets, so it seemed inevitable that the government would ask for the "rescate" as Greece, Ireland and Portugal had already done. On July 11, President Rajoy said in the Congress of Deputies:
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.